- Home
- ELVN vs DX Comparison
ELVN vs DX Comparison
Compare ELVN & DX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVN
- DX
- Stock Information
- Founded
- ELVN 2016
- DX 1987
- Country
- ELVN United States
- DX United States
- Employees
- ELVN N/A
- DX N/A
- Industry
- ELVN Biotechnology: Pharmaceutical Preparations
- DX Real Estate Investment Trusts
- Sector
- ELVN Health Care
- DX Real Estate
- Exchange
- ELVN Nasdaq
- DX Nasdaq
- Market Cap
- ELVN 1.1B
- DX 920.4M
- IPO Year
- ELVN 2020
- DX N/A
- Fundamental
- Price
- ELVN $27.53
- DX $12.21
- Analyst Decision
- ELVN Strong Buy
- DX Strong Buy
- Analyst Count
- ELVN 3
- DX 5
- Target Price
- ELVN $34.33
- DX $13.33
- AVG Volume (30 Days)
- ELVN 309.7K
- DX 2.0M
- Earning Date
- ELVN 11-07-2024
- DX 10-21-2024
- Dividend Yield
- ELVN N/A
- DX 12.81%
- EPS Growth
- ELVN N/A
- DX 197.71
- EPS
- ELVN N/A
- DX 0.09
- Revenue
- ELVN N/A
- DX $49,063,000.00
- Revenue This Year
- ELVN N/A
- DX N/A
- Revenue Next Year
- ELVN N/A
- DX $412.44
- P/E Ratio
- ELVN N/A
- DX $134.75
- Revenue Growth
- ELVN N/A
- DX 12.59
- 52 Week Low
- ELVN $9.80
- DX $9.57
- 52 Week High
- ELVN $27.67
- DX $13.13
- Technical
- Relative Strength Index (RSI)
- ELVN 73.14
- DX 40.83
- Support Level
- ELVN $24.60
- DX $12.38
- Resistance Level
- ELVN $27.55
- DX $12.80
- Average True Range (ATR)
- ELVN 1.41
- DX 0.23
- MACD
- ELVN 0.40
- DX -0.06
- Stochastic Oscillator
- ELVN 98.56
- DX 6.45
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.
About DX Dynex Capital Inc.
Dynex Capital Inc is an internally managed mortgage real estate investment trust, which invests in mortgage-backed securities. The company invests in residential and commercial mortgage-backed securities. Its objective is to provide attractive risk-adjusted returns to shareholders over the long term that are reflective of a leveraged, high quality fixed income portfolio with a focus on capital preservation. Its investments consist principally of Agency mortgage-backed securities including residential MBS and commercial MBS.